Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial.
The Post Coronary Artery Bypass Graft trial is an important milestone that documents the benefits of treating hypercholesterolemia in patients with severe coronary atherosclerosis who have had bypass surgery. In the present article, we highlight the rationale, study design, and results of the Post-CABG study, which was recently published in the New England Journal of Medicine.
Stewart
W J
WJ
Department of Endocrinology, Cleveland Clinic Foundation, OH 44195, USA.
Hoogwerf
B J
BJ
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008148:Lovastatin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012107:Research Design; D014859:Warfarin / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D008078:Cholesterol, LDL; D014859:Warfarin; D008148:Lovastatin